Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Rhea-AI Summary

Acurx Pharmaceuticals (Nasdaq: ACXP) has announced its participation in the Alliance Global Partners (A.G.P) Healthcare Company Showcase on May 21, 2025, at 9:00 a.m. ET. David P. Luci, President & CEO, will engage in a virtual fireside chat presentation.

The company, which specializes in developing small molecule antibiotics for difficult-to-treat bacterial infections, will showcase its lead antibiotic candidate ibezapolstat (IBZ). This drug is prepared to progress to international Phase 3 clinical trials for treating C. difficile infection (CDI).

The presentation will be available via live webcast, with a replay accessible through the News/Events section on the company's website at www.acurxpharma.com.

STATEN ISLAND, N.Y., April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase on Wednesday, May 21, 2025, at 9:00 a.m. ET. The Company's lead antibiotic candidate, ibezapolstat (IBZ), is ready to advance to international Phase 3 clinical trials for treatment of patients with C. difficile infection (CDI).

A live webcast of the presentation can be found here. A replay of the presentation will also be available under the News / Events tab of the Acurx website following the event at www.acurxpharma.com.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials as soon as possible.  The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

Forward-Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

Investor Contact:

Acurx Pharmaceuticals, Inc.
David P. Luci
President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com

View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-alliance-global-partners-agp-healthcare-company-showcase-302438086.html

SOURCE Acurx Pharmaceuticals, Inc.

FAQ

What is the significance of Acurx Pharmaceuticals (ACXP) presenting at the A.G.P Healthcare Showcase?

The presentation provides ACXP an opportunity to showcase their lead antibiotic candidate ibezapolstat (IBZ) to healthcare industry stakeholders, particularly as it prepares for Phase 3 clinical trials for C. difficile infection treatment.

When and where can investors watch ACXP's A.G.P Healthcare Showcase presentation?

The virtual presentation will take place on May 21, 2025, at 9:00 a.m. ET. It will be available via live webcast, with a replay accessible on Acurx's website under the News/Events tab.

What stage is ACXP's ibezapolstat (IBZ) drug development currently in?

Ibezapolstat is ready to advance to international Phase 3 clinical trials for treating patients with C. difficile infection (CDI).

What type of medications is ACXP developing?

ACXP is developing a new class of small molecule antibiotics specifically designed for difficult-to-treat bacterial infections.